The North America Extracorporeal CO2 Removal Devices Market would witness market growth of 6.1% CAGR during the forecast period (2023-2030).
ECCO2R may be employed as a bridge to lung transplantation for patients awaiting lung donor matching. It helps maintain acceptable blood gas levels while waiting for a suitable donor organ. These Devices can be used during severe COPD exacerbations when conventional treatments are insufficient to manage hypercapnia (elevated CO2 levels). It can help avoid intubation and mechanical ventilation in some cases. ECCO2R is considered for patients at high risk of ventilator-associated lung injury, barotrauma, or oxygen toxicity when undergoing mechanical ventilation.
These Devices are crucial in managing acute respiratory distress syndrome (ARDS), a severe and often life-threatening condition characterized by profound respiratory failure. In ARDS, the lungs become severely inflamed and filled with fluid, impairing their ability to oxygenate the blood and eliminate carbon dioxide (CO2). ECCO2R devices are used in ARDS cases to address elevated CO2 levels, a condition known as hypercapnia.
By diverting a portion of the patient's blood to the ECCO2R machine, which employs a specialized membrane to remove excess CO2 and reinfuses the blood with oxygen, these devices help reduce the burden on the compromised lungs. This allows for a gentler and less invasive mechanical ventilation strategy, which can prevent ventilator-induced lung injury (VILI) and minimize further harm to the already fragile lung tissue in ARDS patients. ECCO2R serves as a valuable adjunct therapy in ARDS management, supporting the patient's respiratory needs while facilitating the potential for lung recovery.
COPD is a prevalent respiratory condition in North America, primarily affecting older adults. In the United States, COPD was estimated to affect over 16 million adults in 2023, as per the Centres for Disease Control and Prevention. COPD is a primary cause of hospital admissions associated with a substantial economic burden due to healthcare costs and lost productivity. Thus, the growing prevalence of COPD and asthma in the region will drive the growth of the market.
The US market dominated the North America Extracorporeal CO2 Removal Devices Market, By Country in 2022, and would continue to be a dominant market till 2030; thereby, achieving a market value of $35,046.6 Thousands by 2030. The Canada market is experiencing a CAGR of 8.5% during (2023 - 2030). Additionally, The Mexico market would exhibit a CAGR of 7.5% during (2023 - 2030).
Based on Application, the market is segmented into Bridge to Lung Transplant, Chronic Obstructive Pulmonary Disease (COPD), Acute Respiratory Distress Syndrome (ARDS), and Others. Based on End-Use, the market is segmented into Hospitals, Clinics, Ambulatory Surgical Centers, and Others. Based on Product, the market is segmented into Extracorporeal CO2 Machines, Disposables, and Others. Based on Access, the market is segmented into Arteriovenous & Venovenous. Based on countries, the market is segmented into U.S., Mexico, Canada, and Rest of North America.
Free Valuable Insights: The Extracorporeal CO2 Removal Devices Market is Predict to reach $132.8 Million by 2030, at a CAGR of 7.3%
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Medtronic PLC, Getinge AB, Fresenius Medical Care AG & Co. KGaA , Medica S.P.A., Aferetica srl, LivaNova PLC, ESTOR S.P.A., X-COR Therapeutics
By Application
By End-Use
By Product
By Access
By Country
Unique Offerings Our team of dedicated experts can provide you with attractive expansion opportunities for your business.
